Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

BACKGROUND: Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patients with t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Rajan, Arun, Heery, Christopher R., Thomas, Anish, Mammen, Andrew L., Perry, Susan, O’Sullivan Coyne, Geraldine, Guha, Udayan, Berman, Arlene, Szabo, Eva, Madan, Ravi A., Ballester, Leomar Y., Pittaluga, Stefania, Donahue, Renee N., Tsai, Yo-Ting, Lepone, Lauren M., Chin, Kevin, Ginty, Fiona, Sood, Anup, Hewitt, Stephen M., Schlom, Jeffrey, Hassan, Raffit, Gulley, James L.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805423/
https://ncbi.nlm.nih.gov/pubmed/31639039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0723-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados